2011 Fiscal Year Final Research Report
Individualized Cancer Therapy Using Cancer Testis Antigens
| Project/Area Number |
22650233
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Tumor diagnosis
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Keywords | がん精巣抗原 / 相同組換え修復 / 放射線治療 / 化学療法 / 個別化治療 |
|---|
| Research Abstract |
Cancer testis antigens are assumed to be excellent targets for cancer treatment because their expression is limited to germ cells and cancers of various origins. We investigated therapeutic strategies for cancer expressing these molecules by analyzing their functions. We confirmed that SYCP3 and SMC1., components of synaptonemal complexes formed during meiosis, are cancer testis antigens, and found that their expression in somatic cells inhibits homologous recombination repair of DNA double-stranded breaks. This result indicates that cancers expressing these cancer testis antigens are hypersensitive to treatments that exert anti-tumor activities by inducing DNA double-stranded breaks.
|
